Robert F. Siliciano, M.D., Ph.D., HHMI Investigator
For the staggering number of people infected with HIV (40 million), the best current hope for avoiding the fatal consequences of the infection lies in treatment with highly active antiretroviral therapy (HAART), which consists of combinations of three or more drugs that inhibit HIV reverse transcriptase or protease. Th
Robert F. Siliciano, M.D., Ph.D., HHMI Investigator
Treating hepatitis B patients with the drug entecavir can cause those who are also infected with HIV to become resistant to two of the most important drugs in the anti-HIV arsenal, according to a new report in the New England Journal of Medicine. In findings published June 21, 2007, online in the journal, the researche
In the battles that rage between the human immunodeficiency virus (HIV) and an infected patient s T cells, the rules of engagement are always changing. The T cells adapt continuously to recognize HIV proteins and alert the immune system to launch an attack. But the virus perseveres because it has an exceptional capacit
This information is designed to support, not replace, the relationship that exists between you and your doctor.